CDKN2A and brain glioma: Currently, research on intelligent imaging predicting molecular subtypes of brain gliomas mostly focuses on individual molecular subtypes [38–42], with few studies considering the four high-risk molecular subtypes in LrGGs as a whole (i.e., IDH-wildtype with TERTp-mutation, IDH-wildtype with EGFR amplification, IDH-wildtype with + 7/-10 alterations, IDH-mutation with CDKN2A/B homozygous deletion).